Kerry J Laing

Title: Kerry J Laing: Innovator in HSV Research

Introduction

Kerry J Laing is a notable inventor based in Seattle, WA (US), recognized for his contributions to the field of herpes simplex virus (HSV) research. With a total of 2 patents, Laing has made significant strides in developing therapeutic strategies for HSV infections.

Latest Patents

Laing's latest patents include the invention of antigenic peptides of HSV-2 and methods for using them. This invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. It includes epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells that have specificity for these antigens have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity offers improved anti-viral therapeutic and prophylactic strategies. Compositions containing these antigens or polynucleotides encoding them provide effectively targeted vaccines for the prevention and treatment of HSV infection.

Career Highlights

Throughout his career, Laing has worked with prestigious institutions such as the University of Washington and Fred Hutchinson Cancer Center. His research has focused on understanding the immune response to HSV and developing innovative treatments.

Collaborations

Laing has collaborated with prominent figures in the field, including Lawrence G Corey and Anna Wald, who have also contributed significantly to HSV research.

Conclusion

Kerry J Laing's work in HSV research exemplifies the impact of innovative thinking in the medical field. His patents and collaborations highlight the importance of targeted therapies in combating viral infections.